HER2 Biomarkers

The firm is still designing the study, which will explore the ability of GP2 to prevent recurrence in HER2-postive breast cancer after surgery. 

The Phase III trial will compare Enhertu against Kadcyla as an adjuvant treatment for early-stage HER2-positive breast cancer patients.

The FDA also granted priority review for Enhertu for the treatment of patients with HER2-positive metastatic gastric cancer.

The drug firm expects to begin a Phase I/II tumor-agnostic trial of the drug in genetically defined cancers in the second half of 2021.

The NCCN's research program will put out a request for proposals early next year for studies to investigate neratinib in various molecularly defined cancers.

The company is studying lasofoxifene in combination with Eli Lilly's Verzenio in certain metastatic breast cancer patients with ESR1 mutations in their tumors.

Published data from the ExteNET trial show an overall survival benefit with Nerlynx versus placebo in HER2-positive disease after treatment with Herceptin.

Merck and Seattle Genetics will codevelop the antibody drug conjugate ladiratuzumab vedotin, while Merck gains ex-US commercialization rights to the HER2 inhibitor Tukysa.

The trial will assess the safety and tolerability of Zion's ZN-A-1041 in patients with HER2-positive tumors, including those with brain metastases.